Immunoglobulin G Fc receptor FcγRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 28, Issue 2, 2010, Pages 279-284

  Weng, Wen Kai ^a   Negrin, Robert S ^a   Lavori, Philip ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CD16 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FC RECEPTOR; FC RECEPTOR IIA; GENOMIC DNA; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLELE; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FOLLOW UP; GENOTYPE; HUMAN; INCIDENCE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; GENETIC POLYMORPHISM; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; MIDDLE AGED; NEUTROPENIA; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RECURRENCE;

EID: 74949083067     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.0274     Document Type: Article

References (45)

1. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
2. Horwitz SM, Negrin RS, Blume KG, et al: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777-783, 2004
3. Weng W-K, Levy R: Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003
4. Weng W-K, Levy R: Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome of rituximab treated follicular lymphoma patients. Leuk Lymphoma 50:723-727, 2009
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
6. Shimoni A, Hardan I, Avigdor A, et al: Rituximab reduced relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 122:457-464, 2003
7. Papadaki T, Stamatopoulos K, Stavroyianni N, et al: Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: Report of two cases. Leuk Res 26:597-600, 2002
8. Chaiwatanatorn K, Lee N, Grigg A, et al: Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 121:913-918, 2003
9. Voog E, Morschhauser F, Solal-Celigny P: Neutropenia in patients treated with rituximab. N Engl J Med 348:2691-2694, 2003
10. Dunleavy K, Hakim F, Kim HK, et al: B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106:795-802, 2005
11. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγR IIIa gene. Blood 99:754-758, 2002
12. Negrin RS, Kusnierz-Glaz CR, Still BJ, et al: Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 85:3334-3341, 1995
13. Weng W-K, Czerwinski D, Levy R: Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 109:951-953, 2007
14. Weng W-K, Levy R: Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma 50:1494-1500, 2009
15. McLaughlin P: Late-onset neutropenia following rituximab. Leuk Lymphoma 47:965-966, 2006
16. Cattaneo C, Spedini P, Casair S, et al: Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 47:1013-1017, 2006
17. Kaya H, Keung Y-K, Case D, et al: Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent lowgrade non-Hodgkin's lymphoma after high dose chemotherapy and autologous hematopoietic cell transplant. Biol Blood Marrow Transplant 8:544-549, 2002
18. Fukuno K, Tsurumi H, Ando N, et al: Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. Int J Hematol 84:242-247, 2006
19. Nitta E, Izutsu K, Sato T, et al: A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann Oncol 18:364-369, 2007
20. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
21. Flinn IW, O'Donnell PV, Goodrich A, et al: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:628-632, 2000
22. Lemieux B, Tartas S, Traulle C, et al: Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 33: 921-923, 2004
23. Cairoli R, Grillo G, Tedeschi A, et al: High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 89:361-363, 2004
24. Joyce RM, Regan M, Ottaway J, et al: A phase I-II study for rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol 14:i21-i27, 2003 (suppl 1)
25. Marotte H, Paintaud G, Watier H, et al: Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis 67:893-894, 2008
26. Rios-Fernández R, Gutierrez-Salmeron MT, Callejas-Rubio J-L, et al: Late-onset neutropenia following rituximab in patients with autoimmune disease. Br J Dermatol 157:1271-1273, 2007
27. Daydé D, Ternant D, Ohresser M, et al: Tumor burden influences exposure and response to rituximab: Pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113:3765-3772, 2009
28. Valerius T, Repp R, de Wit TPM, et al: Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931-939, 1993
29. Perussia B, Kobayashi M, Rossi ME, et al: Immune interferon enhances functional properties of human granulocytes: Role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J Immunol 138:765-774, 1987
30. Ueda Y, Kondo M, Kelsoe G: Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 201:1771-1780, 2005
31. Terrier B, Ittah M, Tourneur L, et al: Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 92:e20-e23, 2007
32. Anolik JH, Campbell D, Felgar RE, et al: The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459, 2003
33. Aksoy S, Dizdar O, Hayran M, et al: Infectious complications of rituximab in patients with lymphoma during maintenance therapy: A systematic review and meta-analysis. Leuk Lymphoma 50:357-365, 2009
34. van Oers MHJ, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
35. Miescher S, Spycher MO, Amstutz H, et al: A single recombinant anti-RhD IgG prevents RhD immunization: Association of RhD-positive red blood cell clearance rate with polymorphism in the FcγRIIA and FcγRIIIA genes. Blood 103:4028-4035, 2004
36. Musolino A, Naldi N, Bortesi B, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796, 2008
37. Zhang W, Gordon M, Schultheis AM, et al: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expression metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712-3718, 2007
38. Stavenhagen JB, Gorlatov S, Tuaillon N, et al: Fc Optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res 67:8882-8890, 2007
39. Lazar GA, Dang W, Karki S, et al: Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103:4005-4010, 2006
40. Farag SS, Flinn IW, Modali R, et al: FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103:1472-1474, 2004
41. Treon SP, Hansen M, Branagan AR, et al: Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 23:474-481, 2005
42. Kim DH, Jung HD, Kim JG, et al: FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108:2720-2725, 2006
43. Mitrovic Z, Aurer I, Radman I, et al: FcγRIIIA and FcγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B cell lymphoma. Haematologica 92: 998-999, 2007
44. Carlotti E, Palumbo GA, Oldani E, et al: FcgRIIIA and FcgRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 92:1127-1130, 2007
45. Hagberg H, Gisselbrecht C: Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study. Ann Oncol 17:iv31-iv32, 2006 (suppl 4)